Caixin
BUSINESS & TECH

Merck to Launch Cutting-Edge Cancer Drug in China

A growing number of foreign drugmakers are bringing their most cutting-edge drugs to China, catering to an increasingly affluent populace that is willing to pay for such expensive treatments. Photo: VCG
A growing number of foreign drugmakers are bringing their most cutting-edge drugs to China, catering to an increasingly affluent populace that is willing to pay for such expensive treatments. Photo: VCG

U.S. pharmaceutical giant Merck & Co. has applied to launch one of its core cancer drugs in China, three months after global rival Bristol-Myers Squibb (BMS) applied to sell a similar drug in the lucrative market.

The China Food and Drug Administration (CFDA) this week began to process Merck’s application for Keytruda, the brand name for the injected drug pembrolizumab, according to CFDA’s pipeline database.

ladingImg
You've accessed an article available only to subscribers
Try 4 weeks for $0.99
SUBSCRIBE
Share this article
Open WeChat and scan the QR code
Copyright © 2018 Caixin Global Limited. All Rights Reserved.